Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.

Identifieur interne : 001E22 ( Ncbi/Curation ); précédent : 001E21; suivant : 001E23

Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.

Auteurs : Claudio Lucetti [Italie] ; Paulo Del Dotto ; Gianna Gambaccini ; Roberto Ceravolo ; Chiara Logi ; Caterina Berti ; Giuseppe Rossi ; Maria Cristina Bianchi ; Michela Tosetti ; Luigi Murri ; Ubaldo Bonuccelli

Source :

RBID : pubmed:17722082

English descriptors

Abstract

The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.

DOI: 10.1002/mds.21576
PubMed: 17722082

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:17722082

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.</title>
<author>
<name sortKey="Lucetti, Claudio" sort="Lucetti, Claudio" uniqKey="Lucetti C" first="Claudio" last="Lucetti">Claudio Lucetti</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neuroscience, University of Pisa, Pisa, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neuroscience, University of Pisa, Pisa</wicri:regionArea>
<wicri:noRegion>Pisa</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Del Dotto, Paulo" sort="Del Dotto, Paulo" uniqKey="Del Dotto P" first="Paulo" last="Del Dotto">Paulo Del Dotto</name>
</author>
<author>
<name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name>
</author>
<author>
<name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name>
</author>
<author>
<name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name>
</author>
<author>
<name sortKey="Berti, Caterina" sort="Berti, Caterina" uniqKey="Berti C" first="Caterina" last="Berti">Caterina Berti</name>
</author>
<author>
<name sortKey="Rossi, Giuseppe" sort="Rossi, Giuseppe" uniqKey="Rossi G" first="Giuseppe" last="Rossi">Giuseppe Rossi</name>
</author>
<author>
<name sortKey="Bianchi, Maria Cristina" sort="Bianchi, Maria Cristina" uniqKey="Bianchi M" first="Maria Cristina" last="Bianchi">Maria Cristina Bianchi</name>
</author>
<author>
<name sortKey="Tosetti, Michela" sort="Tosetti, Michela" uniqKey="Tosetti M" first="Michela" last="Tosetti">Michela Tosetti</name>
</author>
<author>
<name sortKey="Murri, Luigi" sort="Murri, Luigi" uniqKey="Murri L" first="Luigi" last="Murri">Luigi Murri</name>
</author>
<author>
<name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="doi">10.1002/mds.21576</idno>
<idno type="RBID">pubmed:17722082</idno>
<idno type="pmid">17722082</idno>
<idno type="wicri:Area/PubMed/Corpus">002537</idno>
<idno type="wicri:Area/PubMed/Curation">002537</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002770</idno>
<idno type="wicri:Area/Ncbi/Merge">001E22</idno>
<idno type="wicri:Area/Ncbi/Curation">001E22</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.</title>
<author>
<name sortKey="Lucetti, Claudio" sort="Lucetti, Claudio" uniqKey="Lucetti C" first="Claudio" last="Lucetti">Claudio Lucetti</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neuroscience, University of Pisa, Pisa, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neuroscience, University of Pisa, Pisa</wicri:regionArea>
<wicri:noRegion>Pisa</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Del Dotto, Paulo" sort="Del Dotto, Paulo" uniqKey="Del Dotto P" first="Paulo" last="Del Dotto">Paulo Del Dotto</name>
</author>
<author>
<name sortKey="Gambaccini, Gianna" sort="Gambaccini, Gianna" uniqKey="Gambaccini G" first="Gianna" last="Gambaccini">Gianna Gambaccini</name>
</author>
<author>
<name sortKey="Ceravolo, Roberto" sort="Ceravolo, Roberto" uniqKey="Ceravolo R" first="Roberto" last="Ceravolo">Roberto Ceravolo</name>
</author>
<author>
<name sortKey="Logi, Chiara" sort="Logi, Chiara" uniqKey="Logi C" first="Chiara" last="Logi">Chiara Logi</name>
</author>
<author>
<name sortKey="Berti, Caterina" sort="Berti, Caterina" uniqKey="Berti C" first="Caterina" last="Berti">Caterina Berti</name>
</author>
<author>
<name sortKey="Rossi, Giuseppe" sort="Rossi, Giuseppe" uniqKey="Rossi G" first="Giuseppe" last="Rossi">Giuseppe Rossi</name>
</author>
<author>
<name sortKey="Bianchi, Maria Cristina" sort="Bianchi, Maria Cristina" uniqKey="Bianchi M" first="Maria Cristina" last="Bianchi">Maria Cristina Bianchi</name>
</author>
<author>
<name sortKey="Tosetti, Michela" sort="Tosetti, Michela" uniqKey="Tosetti M" first="Michela" last="Tosetti">Michela Tosetti</name>
</author>
<author>
<name sortKey="Murri, Luigi" sort="Murri, Luigi" uniqKey="Murri L" first="Luigi" last="Murri">Luigi Murri</name>
</author>
<author>
<name sortKey="Bonuccelli, Ubaldo" sort="Bonuccelli, Ubaldo" uniqKey="Bonuccelli U" first="Ubaldo" last="Bonuccelli">Ubaldo Bonuccelli</name>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Aspartic Acid (analogs & derivatives)</term>
<term>Aspartic Acid (metabolism)</term>
<term>Choline (metabolism)</term>
<term>Creatinine (metabolism)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Magnetic Resonance Imaging</term>
<term>Magnetic Resonance Spectroscopy</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Cortex (drug effects)</term>
<term>Motor Cortex (metabolism)</term>
<term>Motor Cortex (pathology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (pathology)</term>
<term>Pergolide (therapeutic use)</term>
<term>Protons</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en">
<term>Aspartic Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Aspartic Acid</term>
<term>Choline</term>
<term>Creatinine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Dopamine Agonists</term>
<term>Pergolide</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Motor Cortex</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Motor Cortex</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Motor Cortex</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Magnetic Resonance Imaging</term>
<term>Magnetic Resonance Spectroscopy</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Protons</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The objective of this study was to investigate neurochemical and metabolic changes in the motor cortex in a group of de novo Parkinson's disease (PD) patients before and after 6 mo treatment with the dopamine agonist pergolide. Proton magnetic resonance spectroscopy (1H-MRS) has been used to study striatal and cortical metabolism in PD and other parkinsonisms. So far, no studies evaluating possible brain metabolic changes in PD patients before and after dopaminergic therapy have been reported. De novo PD patients (11) and controls (11) underwent clinical evaluation (UPDRS-III motor evaluation) and a first single-voxel 1H-MRS of the motor cortex. 1H-MRS studies were performed using the PROBE-SV System implemented on a 1.5 Tesla Scanner (GE Medical System, Milwaukee, WI). Pergolide was administered up to a dose of 1 mg t.i.d. After 6 mo follow-up, all patients were clinically evaluated and a second single-voxel 1H-MRS was performed. Lower values of Cho/Cr and NAA/Cr ratios were observed in the motor cortex of PD patients compared with controls (P < 0.02 and P < 0.01, respectively). After 6 mo therapy with pergolide (1 mg t.i.d), PD patients showed an improvement in motor performances (P < 0.05) and an increase in Cho/Cr ratios in the motor cortex at the second 1H-MRS evaluation (P < 0.05) was reported. In conclusion, cortical NAA/Cr and Cho/Cr ratios may be impaired in de novo PD. Dopaminergic therapy capable of improving motor function may restore the Cho/Cr ratio in the motor cortex.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E22 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001E22 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:17722082
   |texte=   Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:17722082" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024